Assessment of Non-Vitamin K Antagonist Oral Anticoagulant Dosing Patterns in Turkish Patients with Non-Valvular Atrial Fibrillation: A Multicenter, Cross-Sectional Study with Insights from the ASPECT-NOAC Study Kalp Kapak Hastalığı Olmayan Atriyal Fibrilasyonlu Türk Hastalarda Vitamin K Antagonisti Olmayan Oral Antikoagülan (NOAC) Dozlama Paternlerinin Değerlendirilmesi: ASPECT-NOAC Çalışmasından Görüşlerle Çok Merkezli, Kesitsel Bir Çalışma
Turk Kardiyoloji Dernegi Arsivi, cilt.52, sa.8, ss.574-580, 2024 (ESCI, Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 52 Sayı: 8
- Basım Tarihi: 2024
- Doi Numarası: 10.5543/tkda.2024.47718
- Dergi Adı: Turk Kardiyoloji Dernegi Arsivi
- Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.574-580
- Anahtar Kelimeler: Anticoagulants, atrial fibrillation, dosing pattern, non-vitamin K antagonist oral anticoagulants, patient medication knowledge
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Objective: We aimed to assess the real-world label adherence of non-vitamin K antagonis oral anticoagulant (NOAC) dosing patterns, including apixaban, edoxaban, and rivaroxaban, i Turkish patients with atrial fibrillation. Methods: This was an observational, prospective, cross-sectional, multicenter study. Patient with atrial fibrillation (AF) who were prescribed NOACs within the last 4 months were recruite from 34 cardiology clinics in Türkiye. Baseline data were initially collected, and patien awareness was evaluated at 3-4 weeks. Results: A total of 903 patients were enrolled in the study. The mean age was 72.84 ± 10.1 years. We found that 140 (15.5%), 721 (79.8%), and 42 patients (4.7%) were prescribe off-label low, on-label, and off-label high dosing, respectively. The age of the patients in th on-label group was significantly lower than that of those in the off-label low and off-label hig groups (both P < 0.001). Female patients were more frequently observed in the off-label hig group (P = 0.019). The body mass index values of the patients in the off-label high-dose grou were significantly lower than those in the other groups (P < 0.001). The perception of incom levels also revealed significant differences between the groups (P = 0.010). Furthermore, th HAS-BLED scores (the Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding Histor or Predisposition, Labile International Normalized Ratio, Elderly, Drugs/Alcohol Concomitantly were significantly lower in the on-label group than in the other groups (P < 0.001). Similarl the CHA2DS2-VASc [the Congestive Heart Failure, Hypertension, Age ≥75 (Doubled), Diabetes Stroke (Doubled), Vascular Disease, Age 65-74, and Sex Category (Female)] scores wer significantly lower in the on-label group than in the off-label group (P < 0.001). Conclusion: The clinical impact off-label NOAC prescriptions may vary. Therefore, raisin clinician awareness about proper NOAC dosing could aid in improve the outcomes.